P044 C1q status and titer of de novo donor specific antibodies are not predictors of allograft survival

Wiebe, Chris; Gareau, Alison J.; Pochinco, Denise; Gibson, Ian W.; Ho, Julie; Birk, Patricia E.; Blydt-Hansen, Tom; Karpinski, Martin; Goldberg, Aviva; Storsley, Leroy; Rush, David; Nickerson, Peter

doi:10.1016/j.humimm.2016.07.109

Cited by 23 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In parallel, at bead level, we also observed that MFI from untreated serum was a poor predictor of complement interference occurrence in comparison with the treated condition. Interestingly, the optimal EDTA MFI thresholds for predicting complement interference described here are similar to those we recently reported for T‐lymphocyte complement‐dependent cytotoxicity crossmatch results prediction, but also to those we and others described for C1q‐ and C3d‐binding ability . These concordant findings emphasize the tight link that associates the ability of HLA antibodies to strongly activate the complement and the interference phenomenon.…”

Section: Discussionsupporting

confidence: 90%

Prevalence, distribution and amplitude of the complement interference phenomenon in single antigen flow beads assays

Guidicelli

Visentin

Franchini

et al. 2018

HLA

View full text Add to dashboard Cite

HLA antibody detection with single antigen flow beads (SAFB) assays is impaired by complement interference whose frequency, predictability and distribution among HLA antigens have not been analyzed in large cohorts. We compared in two patients' cohorts the routine follow-up SAFB profiles obtained in class I (n = 129) and class II (n = 85) with and without ethylenediaminetetraacetic acid (EDTA)-treatment. The presence of complement interference was defined according to the reproducibility of the SAFB assays evaluated with our class I and II routine positive control sera. Interference occurred in 29.5% and 45.9% of patients in class I and II, respectively. In the untreated condition, at serum level, neither the number of positive beads, the highest bead mean fluorescence intensity (MFI) nor MFI at bead level, satisfactorily predicted interference. HLA-C were the least affected among class I beads. HLA-DQ beads were the most affected in class II. At least one antibody specificity was falsely negative without EDTA for about 3% of sera in class I and 9% in class II. EDTA-treatment did not significantly modify the low-MFI strengths (500-3000 range). This study emphasizes the high frequency of complement interference and the importance and advantages of systematically pretreating sera with EDTA before performing SAFB assays.

show abstract

Section: Discussionsupporting

confidence: 90%

Prevalence, distribution and amplitude of the complement interference phenomenon in single antigen flow beads assays

Guidicelli

Visentin

Franchini

et al. 2018

HLA

View full text Add to dashboard Cite

show abstract

“… Recipients with post‐transplant DSA: recipients showing post‐transplant DSA, either de novo DSA or pre‐transplant DSA that were maintained after transplant. The definition of de novo DSA was any DSA identified at least a week after transplant that was absent at any time prior to transplant (each recipient had at least one pre‐transplant SAB test) Recipients with no post‐transplant DSA: recipients who did not show DSA pre‐transplant or in any of the post‐transplant studies. …”

Section: Methodsmentioning

confidence: 99%

The role of complement‐fixing donor‐specific antibodies identified by a C1q assay after heart transplantation

Farrero¹,

Pando

Luo

et al. 2017

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…The major determinant of C1q or C3d binding on SAB is the amount of DSA, which can be approximated by the MFI value . It is not surprising that most studies found a very strong correlation of the MFI value and C1q or C3d binding . While some studies including a recent meta‐analysis found that C1q or C3d binding assays add some prediction beyond the MFI value, other studies did not .…”

Section: Modifications Of the Generic Sab Assaymentioning

confidence: 99%

Caveats of HLA antibody detection by solid‐phase assays

2019

View full text Add to dashboard Cite

All authors contributed equally to the review SUMMARY Solid-phase assays for human leukocyte antigens (HLA) antibody detection have clearly revolutionized the field of HLA diagnostics and transplantation. The key advantages are a high sensitivity and specificity for detection of HLA antibodies compared with cell-based assays, as well as the potential for standardization. Solid-phase assays enabled the broad introduction of tools such as "virtual crossmatching" and "calculated panel reactive antibodies," which are essential components in many organ allocation systems, kidney-paired donation programs, and center-specific immunological risk stratification procedures. The most advanced solid-phase assays are the socalled single antigen beads (SAB). They are available now for more than 15 years, and the transplant community embraced their significant advantages. However, SAB analysis and interpretation is complex and many pitfalls have to be considered. In this review, we will discuss problems, limitations, and challenges using SAB. Furthermore, we express our wishes for improvements of SAB as well as their future use for immunological assessment and research purposes.

show abstract

P044 C1q status and titer of de novo donor specific antibodies are not predictors of allograft survival

Cited by 23 publications

References 0 publications

Prevalence, distribution and amplitude of the complement interference phenomenon in single antigen flow beads assays

Prevalence, distribution and amplitude of the complement interference phenomenon in single antigen flow beads assays

The role of complement‐fixing donor‐specific antibodies identified by a C1q assay after heart transplantation

Caveats of HLA antibody detection by solid‐phase assays

Contact Info

Product

Resources

About